	US 12,227,808 B2
	Compostions and methods for diagnosing lung cancers using gene expression profiles
Michael Showe, Media, PA (US); Louise C. Showe, Media, PA (US); and Andrew V. Kossenkov, Huntingdon Valley, PA (US)
Appl. No. 16/954,370
Filed by The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
PCT Filed Dec. 19, 2018, PCT No. PCT/US2018/066531 § 371(c)(1), (2) Date Jun. 16, 2020, PCT Pub. No. WO2019/126343, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/752,163, filed on Oct. 29, 2018.
Claims priority of provisional application 62/607,756, filed on Dec. 19, 2017.
Prior Publication US 2021/0079479 A1, Mar. 18, 2021
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)]

4 Claims

1. A set of multiple cDNA polynucleotides, cDNA oligonucleotides, or cDNA ligands, consisting of cDNA polynucleotides, cDNA oligonucleotides, or cDNA ligands each of which hybridize to a gene, gene fragment, or gene transcript in a group consisting of SLC25A20, P2RY5, DNAJB1, CCND3, CD160, MERTK, BCOR, ABCA5, RNASE2, IGFBP7, ITGAL, DYNC2LI1, EEF1B2, RAG1, DDIT4, ARG1, TBC1D12, AZI2, LOC100130229, STOM, MED16, EMR4, REPIN1, DNAJB6, IDO1, PSMB7, HSP90AB1, CABC1, PRPF3, PSMB8, TRIM39, CD48, CDH5, KLRC1, TUG1, PIM2, CLPTM1, REPS1, USP9Y, AFTPH, SLC6A12, wherein the set binds each gene, gene fragment, or gene transcript in the group.